SG Americas Securities LLC Buys 7,141 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

SG Americas Securities LLC raised its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 31.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 30,086 shares of the company’s stock after purchasing an additional 7,141 shares during the quarter. SG Americas Securities LLC’s holdings in Nurix Therapeutics were worth $567,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in shares of Nurix Therapeutics by 8.8% during the third quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company’s stock worth $78,243,000 after buying an additional 280,240 shares during the period. Geode Capital Management LLC grew its holdings in Nurix Therapeutics by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company’s stock worth $32,544,000 after acquiring an additional 126,306 shares during the period. Millennium Management LLC raised its position in shares of Nurix Therapeutics by 60.2% in the 2nd quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock worth $12,514,000 after acquiring an additional 225,374 shares in the last quarter. FMR LLC raised its position in shares of Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after acquiring an additional 511,256 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. acquired a new position in shares of Nurix Therapeutics in the 3rd quarter valued at about $12,432,000.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $19.71 on Friday. The business’s 50 day moving average price is $20.09 and its 200-day moving average price is $22.39. Nurix Therapeutics, Inc. has a 1 year low of $7.79 and a 1 year high of $29.56. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -6.82 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 63.38%. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NRIX. Royal Bank of Canada raised their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday. UBS Group started coverage on shares of Nurix Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $35.00 price objective for the company. Stifel Nicolaus boosted their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. BTIG Research initiated coverage on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price target for the company. Finally, HC Wainwright increased their price objective on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.71.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the transaction, the chief financial officer now directly owns 39,549 shares in the company, valued at approximately $785,047.65. The trade was a 6.64 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.20% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.